Eric Ostertag - Oct 11, 2021 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Oct 11, 2021
Transactions value $
$169,504
Form type
4
Date filed
10/13/2021, 06:59 PM
Previous filing
Oct 5, 2021
Next filing
Nov 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Options Exercise $170K +18.5K +2.73% $9.15 696K Oct 11, 2021 Direct F1
holding PSTX Common Stock 3.67M Oct 11, 2021 See footnote F2
holding PSTX Common Stock 3.37M Oct 11, 2021 See footnote F3
holding PSTX Common Stock 629K Oct 11, 2021 See footnote F4
holding PSTX Common Stock 961K Oct 11, 2021 See footnote F5
holding PSTX Common Stock 161K Oct 11, 2021 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Options Exercise $0 -18.5K -2.44% $0.00 741K Oct 11, 2021 Common Stock 18.5K $9.15 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,482 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2021.
F2 The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
F3 The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F4 The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
F5 The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
F6 The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
F7 12.5% of the shares originally subject to the stock option vested and became exercisable on August 4, 2021, and the remaining shares vest in 42 equal monthly installments thereafter.